OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST

Their core work

Oxford University Hospitals NHS Foundation Trust is one of the UK's largest NHS teaching hospital trusts, operating major hospitals in Oxford including the John Radcliffe, Churchill, and Nuffield Orthopaedic Centre. In EU research, they function as a clinical implementation partner — contributing hospital infrastructure, surgical teams, and regulated patient cohorts rather than laboratory research. In HIPGEN, they served as a clinical trial site for a Phase III study testing placenta-derived cell therapy for hip fracture recovery in elderly patients. In STEP CHANGE, they brought frontline health-sector experience to a European citizen science initiative spanning health, conservation, and energy research.

What they specialise in

How they've shifted over time

OUH's two H2020 projects reveal a clear shift in how they engage with EU research. Their first project (HIPGEN, starting 2018) was firmly biomedical — a Phase III randomised trial in orthopaedic surgery, testing a specific cell therapy product with regulated patient access. Their second project (STEP CHANGE, starting 2021) moved into science governance and public engagement, with keywords like citizen science, RRI, gender and science, and participatory evaluation replacing surgical and clinical terms entirely. Whether this reflects a deliberate expansion of their research portfolio or simply opportunistic participation is hard to determine from two data points, but the direction is from clinical execution toward science-society interface work.

OUH appears to be broadening beyond purely clinical trial hosting toward health research methodology and public participation, making them a plausible partner for projects that need both regulated patient access and credible community engagement in health contexts.

How they like to work

OUH has participated exclusively as a consortium partner across both H2020 projects, which is typical for NHS organisations whose primary asset is patient access and clinical infrastructure rather than project management capacity. Their 27 consortium partners across 14 countries from just two projects indicates they consistently join large, multi-partner European consortia rather than small bilateral collaborations. They are brought in for a specific capability — running regulated trials or lending NHS legitimacy to health-facing citizen science — not for coordinating or shaping project direction.

With 27 unique partners across 14 countries from only 2 projects, OUH consistently operates within large international consortia — their per-project partner density is high. No geographic concentration is visible; their network reflects the broad European spread typical of RIA-funded Health and Society projects.

What sets them apart

As an NHS Foundation Trust rather than a university, OUH brings something most research organisations cannot: genuine hospital-grade clinical infrastructure — operating theatres, ethics-approved patient cohorts, surgical teams, and NHS governance frameworks — directly into EU consortia. This is particularly valuable for late-stage clinical validation (Phase III) where access to real patients in a regulated care setting is the critical bottleneck. Their emerging engagement with citizen science and RRI adds a second dimension, giving them credibility as a health-sector voice in science-society projects that need institutional legitimacy from frontline care rather than academia.

Highlights from their portfolio

• HIPGEN
  A Phase III randomised clinical trial — the most demanding and expensive stage of clinical validation — testing a novel cell therapy derived from placental tissue for hip fracture recovery in elderly patients, where OUH contributed real-world surgical and patient infrastructure.
• STEP CHANGE
  The largest-funded of OUH's two projects (EUR 159,177), spanning health, conservation, and energy through citizen science, revealing an unexpected breadth for an NHS clinical organisation and the highest per-project EC contribution they received.